戴维医疗(300314) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥157,862,759.12, representing a 61.55% increase compared to ¥97,715,502.09 in the same period last year[5] - Net profit attributable to shareholders reached ¥50,019,287.49, a significant increase of 421.75% from ¥9,586,811.39 in the previous year[5] - Basic earnings per share rose to ¥0.1737, up 421.62% from ¥0.0333 in the previous year[5] - Total operating revenue for Q1 2023 reached ¥157,862,759.12, a significant increase of 61.6% compared to ¥97,715,502.09 in the same period last year[22] - Net profit for Q1 2023 was ¥50,019,287.49, compared to ¥9,586,811.39 in Q1 2022, reflecting a growth of 421.5%[23] - The total comprehensive income for the first quarter of 2023 was CNY 50,019,287.49, compared to CNY 9,586,811.39 in the same period last year, representing a significant increase[24] - Basic and diluted earnings per share for the first quarter were both CNY 0.1737, up from CNY 0.0333 year-over-year[24] Cash Flow - The net cash flow from operating activities improved to ¥6,903,274.52, compared to a negative cash flow of ¥17,914,205.73 in the same quarter last year, marking a 138.54% increase[5] - Cash inflow from operating activities was CNY 164,362,355.66, an increase from CNY 113,866,702.84 in the previous year[25] - The net cash flow from operating activities was CNY 6,903,274.52, a turnaround from a negative CNY 17,914,205.73 in the same period last year[25] - The net cash flow from investing activities was CNY 15,754,710.15, down from CNY 52,502,957.04 year-over-year[27] - The company reported a cash outflow of CNY 340,000,000.00 related to investment activities, compared to CNY 300,000,000.00 in the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,282,938,126.23, a 2.41% increase from ¥1,252,694,543.64 at the end of the previous year[5] - Total liabilities decreased to ¥173,810,887.79 from ¥193,390,231.36, a reduction of 10.1%[20] - The total current assets increased to ¥956,546,111.80 from ¥922,874,746.07, showing a growth of approximately 3.7%[18] - The total equity attributable to shareholders increased to ¥1,109,127,238.44 from ¥1,059,304,312.28, reflecting a growth of 4.7%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,821[12] - The top three shareholders hold significant stakes: Chen Zaihong (24.69%, 71,108,200 shares), Chen Yunqin (21.12%, 60,820,000 shares), and Chen Zaiwei (20.25%, 58,320,000 shares)[12] - The top ten shareholders include various investment funds, with the largest being a mix of individual and institutional investors[12] - The company has a total of 98,645,352 shares under lock-up agreements, primarily due to executive lock-up policies[16] Operational Highlights - The company reported a significant increase in accounts receivable, which rose by 78.41% to ¥30,397,727.36, attributed to increased credit limits for distributors[9] - The company experienced a 106.03% increase in prepayments, totaling ¥16,711,821.99, due to higher advance payments for materials and testing fees[9] - Research and development expenses for Q1 2023 were ¥8,627,320.97, an increase of 11.7% from ¥7,723,486.29 in the previous year[22] - The company plans to continue its market expansion and product development strategies in the upcoming quarters[12] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20] Investment Income - Investment income for the quarter was ¥6,596,225.75, a recovery from a loss of ¥12,519,228.93 in the same period last year[9] - The company reported an investment income of ¥6,596,225.75, recovering from a loss of ¥12,519,228.93 in the same quarter last year[23] Inventory and Cash Equivalents - Inventory at the end of Q1 2023 was ¥154,769,528.07, up from ¥148,267,523.40 at the beginning of the year, reflecting a growth of about 4.3%[18] - The company's cash and cash equivalents at the end of Q1 2023 amounted to ¥410,519,510.89, an increase from ¥390,938,480.54 at the beginning of the year[18] - The cash and cash equivalents at the end of the period amounted to CNY 409,457,239.69, an increase from CNY 369,011,171.40 at the end of the previous year[27] Other Information - The company has no preferred shareholders as of the reporting period[12] - The first quarter report was not audited[28]